Mozobil (Plerixafor) 24mg/1.2mL Injection China | Sanofi | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Mozobil (plerixafor) — China-Mainland Version
Mozobil is the originator brand of plerixafor, a small-molecule CXCR4 chemokine receptor antagonist developed by Sanofi (Genzyme). Plerixafor blocks the binding of CXCR4 to its ligand stromal cell-derived factor-1 alpha (SDF-1α), which in turn releases haematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood. The China-Mainland version is supplied as a 24 mg/1.2 mL single-dose vial (20 mg/mL) for subcutaneous injection, manufactured by Sanofi.
What Is Mozobil Used For?
Mozobil is used together with granulocyte colony-stimulating factor (G-CSF) to mobilise haematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation. It is indicated for adults with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) who need stem cells collected for an autologous transplant.
How Does Mozobil Work?
Haematopoietic stem cells normally stay anchored in the bone marrow through the interaction between CXCR4 on the stem-cell surface and SDF-1α in the marrow stroma. Plerixafor reversibly blocks this CXCR4–SDF-1α interaction, causing the stem cells to detach and move into the bloodstream. When given after several days of G-CSF, plerixafor significantly increases the number of CD34+ stem cells available for apheresis collection, improving the success and speed of stem-cell harvest.
Indications
In China, Mozobil is indicated, in combination with G-CSF, to mobilise haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. It is intended for patients whose stem-cell collection would otherwise be difficult or unsuccessful.
Dosage
Plerixafor is given by subcutaneous injection at a dose of 0.24 mg/kg once daily, starting after 4 days of G-CSF treatment and given about 11 hours before each apheresis session, for up to 4 consecutive days. For patients weighing 83 kg or less, a fixed dose of 20 mg may be used instead of weight-based dosing. In patients with moderate or severe renal impairment (creatinine clearance ≤ 50 mL/min), the dose is reduced by one third, and the daily dose must not exceed 27 mg.
Side Effects
The most common side effects are diarrhoea, nausea, fatigue, injection-site reactions, headache, arthralgia, dizziness and vomiting. Plerixafor can also cause an increase in circulating white blood cells and a decrease in platelet counts, and in rare cases splenomegaly or allergic reactions. Patients are monitored during and for at least 30 minutes after each injection for signs of hypersensitivity.
Storage
Mozobil vials are stored at controlled room temperature and protected from light. GLT supplies the genuine Sanofi product with full batch documentation, and we confirm cold-chain or temperature-controlled handling requirements to your destination where applicable.
Why Choose China-Sourced Mozobil?
Sourcing Mozobil from the China market provides access to the genuine Sanofi originator product at a cost that is generally in line with or more favourable than several Western list prices. Plerixafor is an important, sometimes difficult-to-source specialty medicine, and GLT's China-sourced supply offers a reliable channel for institutions and individual patients preparing for autologous stem-cell transplantation, backed by verified batch documentation and responsive support.
How to Order
To order Mozobil (plerixafor) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, vial size and delivery timelines to your country, and we support both healthcare institutions and individual patients.
FAQ
Is Mozobil a chemotherapy drug? No. Mozobil is not a chemotherapy agent. It is a haematopoietic stem-cell mobiliser that releases stem cells from the bone marrow so they can be collected for an autologous transplant.
How is Mozobil different from G-CSF alone? G-CSF alone mobilises stem cells in many patients, but some patients do not collect enough stem cells. Adding Mozobil after G-CSF markedly improves stem-cell yields and shortens the time to reach the collection target.
Is the China-Mainland version of Mozobil the same product? Yes. It is the same plerixafor molecule from Sanofi, supplied in the 24 mg/1.2 mL single-dose vial with the China-Mainland label.